Entecavir Monotherapy Improves Renal Function in Patients Developing Renal Side Effects During Long-Term Tenofovir Treatment Without Compromising Virological Response: A Multicenter Real-Life Study in 103 Patients

Introduction: Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for chronic hepatitis B (CHB) patients. However, reduced estimated glomerular filtration rate (eGFR), hypophosphatemia and Fanconi syndrome have been reported in some TDF-treated patients. We assessed whether entecavir (ETV) may be a safe and effective rescue strategy for such patients.